National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts.org
Search Results

This is VAERS ID 629007

Government Disclaimer on use of this data

History of Changes from the VAERS Wayback Machine

First Appeared on 4/14/2016

VAERS ID: 629007
VAERS Form:
Age:16.0
Sex:Female
Location:Arizona
Vaccinated:2015-12-16
Onset:0000-00-00
Submitted:2016-03-23
Entered:2016-03-23
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MEN: MENINGOCOCCAL (NO BRAND NAME) / UNKNOWN MANUFACTURER - / - AR / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS - / 0 AR / IM

Administered by: Other      Purchased by: Other
Symptoms: Injection site erythema, Injection site mass, Injection site pain, Injection site warmth, Myalgia

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016037781

Write-up: This case was reported by a consumer via call center representative and described the occurrence of injection site lump in a 16-year-old female patient who received BEXSERO. Concomitant products included Meningococcal polysaccharide groups A, C, W-135, Y conjugate vaccine. On 16th December 2015, the patient received the 1st dose of BEXSERO (intramuscular). On an unknown date, an unknown time after receiving BEXSERO, the patient experienced injection site lump and injection site warmth. On an unknown date, the outcome of the injection site lump and injection site warmth were unknown. It was unknown if the reporter considered the injection site lump and injection site warmth to be related to BEXSERO. Additional details were received as follows: The patient received the 1st dose in the series of BEXSERO. She also received a meningococcal vaccine on the same day (she believed it might have been brand name MENVEO, but was unsure). The 2 vaccines were administered in different arms. The patient developed a golf-ball sized lump at the site of the BEXSERO vaccine. The lump was red, warm to the touch, and sore for 1 month. The muscle soreness was severe enough to prevent the patient from driving. The patient attempted applying heat and ice, but the pain did not resolve. The patient also took over-the-counter pain medications to relieve the pain. When the patient presented to the clinic for the second BEXSERO injection, the lump had decreased in size, but was still present at the site of the previous injection. The patient''s mother requested that the second BEXSERO injection be administered slightly lower on the muscle and the patient did not have an adverse reaction to the second BEXSERO injection.


Changed on 9/14/2017

VAERS ID: 629007 Before After
VAERS Form:(blank) 1
Age:16.0
Sex:Female
Location:Arizona
Vaccinated:2015-12-16
Onset:0000-00-00
Submitted:2016-03-23
Entered:2016-03-23
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MEN: MENINGOCOCCAL (NO BRAND NAME) / UNKNOWN MANUFACTURER - / - UNK AR / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS - / 0 1 AR / IM

Administered by: Other      Purchased by: Other
Symptoms: Injection site erythema, Injection site mass, Injection site pain, Injection site warmth, Myalgia

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016037781

Write-up: This case was reported by a consumer via call center representative and described the occurrence of injection site lump in a 16-year-old female patient who received BEXSERO. Concomitant products included Meningococcal polysaccharide groups A, C, W-135, Y conjugate vaccine. On 16th December 2015, the patient received the 1st dose of BEXSERO (intramuscular). On an unknown date, an unknown time after receiving BEXSERO, the patient experienced injection site lump and injection site warmth. On an unknown date, the outcome of the injection site lump and injection site warmth were unknown. It was unknown if the reporter considered the injection site lump and injection site warmth to be related to BEXSERO. Additional details were received as follows: The patient received the 1st dose in the series of BEXSERO. She also received a meningococcal vaccine on the same day (she believed it might have been brand name MENVEO, but was unsure). The 2 vaccines were administered in different arms. The patient developed a golf-ball sized lump at the site of the BEXSERO vaccine. The lump was red, warm to the touch, and sore for 1 month. The muscle soreness was severe enough to prevent the patient from driving. The patient attempted applying heat and ice, but the pain did not resolve. The patient also took over-the-counter pain medications to relieve the pain. When the patient presented to the clinic for the second BEXSERO injection, the lump had decreased in size, but was still present at the site of the previous injection. The patient''s mother requested that the second BEXSERO injection be administered slightly lower on the muscle and the patient did not have an adverse reaction to the second BEXSERO injection.


Changed on 2/14/2018

VAERS ID: 629007 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:Arizona
Vaccinated:2015-12-16
Onset:0000-00-00
Submitted:2016-03-23
Entered:2016-03-23
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MEN: MENINGOCOCCAL (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK AR / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS - / 1 AR / IM

Administered by: Other      Purchased by: Other
Symptoms: Injection site erythema, Injection site mass, Injection site pain, Injection site warmth, Myalgia

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016037781

Write-up: This case was reported by a consumer via call center representative and described the occurrence of injection site lump in a 16-year-old female patient who received BEXSERO. Concomitant products included Meningococcal polysaccharide groups A, C, W-135, Y conjugate vaccine. On 16th December 2015, the patient received the 1st dose of BEXSERO (intramuscular). On an unknown date, an unknown time after receiving BEXSERO, the patient experienced injection site lump and injection site warmth. On an unknown date, the outcome of the injection site lump and injection site warmth were unknown. It was unknown if the reporter considered the injection site lump and injection site warmth to be related to BEXSERO. Additional details were received as follows: The patient received the 1st dose in the series of BEXSERO. She also received a meningococcal vaccine on the same day (she believed it might have been brand name MENVEO, but was unsure). The 2 vaccines were administered in different arms. The patient developed a golf-ball sized lump at the site of the BEXSERO vaccine. The lump was red, warm to the touch, and sore for 1 month. The muscle soreness was severe enough to prevent the patient from driving. The patient attempted applying heat and ice, but the pain did not resolve. The patient also took over-the-counter pain medications to relieve the pain. When the patient presented to the clinic for the second BEXSERO injection, the lump had decreased in size, but was still present at the site of the previous injection. The patient''s mother requested that the second BEXSERO injection be administered slightly lower on the muscle and the patient did not have an adverse reaction to the second BEXSERO injection.


Changed on 6/14/2018

VAERS ID: 629007 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:Arizona
Vaccinated:2015-12-16
Onset:0000-00-00
Submitted:2016-03-23
Entered:2016-03-23
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MEN: MENINGOCOCCAL (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK AR / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS - / 1 AR / IM

Administered by: Other      Purchased by: Other
Symptoms: Injection site erythema, Injection site mass, Injection site pain, Injection site warmth, Myalgia

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016037781

Write-up: This case was reported by a consumer via call center representative and described the occurrence of injection site lump in a 16-year-old female patient who received BEXSERO. Concomitant products included Meningococcal polysaccharide groups A, C, W-135, Y conjugate vaccine. On 16th December 2015, the patient received the 1st dose of BEXSERO (intramuscular). On an unknown date, an unknown time after receiving BEXSERO, the patient experienced injection site lump and injection site warmth. On an unknown date, the outcome of the injection site lump and injection site warmth were unknown. It was unknown if the reporter considered the injection site lump and injection site warmth to be related to BEXSERO. Additional details were received as follows: The patient received the 1st dose in the series of BEXSERO. She also received a meningococcal vaccine on the same day (she believed it might have been brand name MENVEO, but was unsure). The 2 vaccines were administered in different arms. The patient developed a golf-ball sized lump at the site of the BEXSERO vaccine. The lump was red, warm to the touch, and sore for 1 month. The muscle soreness was severe enough to prevent the patient from driving. The patient attempted applying heat and ice, but the pain did not resolve. The patient also took over-the-counter pain medications to relieve the pain. When the patient presented to the clinic for the second BEXSERO injection, the lump had decreased in size, but was still present at the site of the previous injection. The patient''s mother requested that the second BEXSERO injection be administered slightly lower on the muscle and the patient did not have an adverse reaction to the second BEXSERO injection.


Changed on 8/14/2018

VAERS ID: 629007 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:Arizona
Vaccinated:2015-12-16
Onset:0000-00-00
Submitted:2016-03-23
Entered:2016-03-23
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MEN: MENINGOCOCCAL (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK AR / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS - / 1 AR / IM

Administered by: Other      Purchased by: Other
Symptoms: Injection site erythema, Injection site mass, Injection site pain, Injection site warmth, Myalgia

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016037781

Write-up: This case was reported by a consumer via call center representative and described the occurrence of injection site lump in a 16-year-old female patient who received BEXSERO. Concomitant products included Meningococcal polysaccharide groups A, C, W-135, Y conjugate vaccine. On 16th December 2015, the patient received the 1st dose of BEXSERO (intramuscular). On an unknown date, an unknown time after receiving BEXSERO, the patient experienced injection site lump and injection site warmth. On an unknown date, the outcome of the injection site lump and injection site warmth were unknown. It was unknown if the reporter considered the injection site lump and injection site warmth to be related to BEXSERO. Additional details were received as follows: The patient received the 1st dose in the series of BEXSERO. She also received a meningococcal vaccine on the same day (she believed it might have been brand name MENVEO, but was unsure). The 2 vaccines were administered in different arms. The patient developed a golf-ball sized lump at the site of the BEXSERO vaccine. The lump was red, warm to the touch, and sore for 1 month. The muscle soreness was severe enough to prevent the patient from driving. The patient attempted applying heat and ice, but the pain did not resolve. The patient also took over-the-counter pain medications to relieve the pain. When the patient presented to the clinic for the second BEXSERO injection, the lump had decreased in size, but was still present at the site of the previous injection. The patient''s mother requested that the second BEXSERO injection be administered slightly lower on the muscle and the patient did not have an adverse reaction to the second BEXSERO injection.


Changed on 9/14/2018

VAERS ID: 629007 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:Arizona
Vaccinated:2015-12-16
Onset:0000-00-00
Submitted:2016-03-23
Entered:2016-03-23
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MEN: MENINGOCOCCAL (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK AR / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS - / 1 AR / IM

Administered by: Other      Purchased by: Other
Symptoms: Injection site erythema, Injection site mass, Injection site pain, Injection site warmth, Myalgia

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016037781

Write-up: This case was reported by a consumer via call center representative and described the occurrence of injection site lump in a 16-year-old female patient who received BEXSERO. Concomitant products included Meningococcal polysaccharide groups A, C, W-135, Y conjugate vaccine. On 16th December 2015, the patient received the 1st dose of BEXSERO (intramuscular). On an unknown date, an unknown time after receiving BEXSERO, the patient experienced injection site lump and injection site warmth. On an unknown date, the outcome of the injection site lump and injection site warmth were unknown. It was unknown if the reporter considered the injection site lump and injection site warmth to be related to BEXSERO. Additional details were received as follows: The patient received the 1st dose in the series of BEXSERO. She also received a meningococcal vaccine on the same day (she believed it might have been brand name MENVEO, but was unsure). The 2 vaccines were administered in different arms. The patient developed a golf-ball sized lump at the site of the BEXSERO vaccine. The lump was red, warm to the touch, and sore for 1 month. The muscle soreness was severe enough to prevent the patient from driving. The patient attempted applying heat and ice, but the pain did not resolve. The patient also took over-the-counter pain medications to relieve the pain. When the patient presented to the clinic for the second BEXSERO injection, the lump had decreased in size, but was still present at the site of the previous injection. The patient''s mother requested that the second BEXSERO injection be administered slightly lower on the muscle and the patient did not have an adverse reaction to the second BEXSERO injection.


Changed on 10/14/2018

VAERS ID: 629007 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:Arizona
Vaccinated:2015-12-16
Onset:0000-00-00
Submitted:2016-03-23
Entered:2016-03-23
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MEN: MENINGOCOCCAL (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK AR / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS - / 1 AR / IM

Administered by: Other      Purchased by: Other
Symptoms: Injection site erythema, Injection site mass, Injection site pain, Injection site warmth, Myalgia

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016037781

Write-up: This case was reported by a consumer via call center representative and described the occurrence of injection site lump in a 16-year-old female patient who received BEXSERO. Concomitant products included Meningococcal polysaccharide groups A, C, W-135, Y conjugate vaccine. On 16th December 2015, the patient received the 1st dose of BEXSERO (intramuscular). On an unknown date, an unknown time after receiving BEXSERO, the patient experienced injection site lump and injection site warmth. On an unknown date, the outcome of the injection site lump and injection site warmth were unknown. It was unknown if the reporter considered the injection site lump and injection site warmth to be related to BEXSERO. Additional details were received as follows: The patient received the 1st dose in the series of BEXSERO. She also received a meningococcal vaccine on the same day (she believed it might have been brand name MENVEO, but was unsure). The 2 vaccines were administered in different arms. The patient developed a golf-ball sized lump at the site of the BEXSERO vaccine. The lump was red, warm to the touch, and sore for 1 month. The muscle soreness was severe enough to prevent the patient from driving. The patient attempted applying heat and ice, but the pain did not resolve. The patient also took over-the-counter pain medications to relieve the pain. When the patient presented to the clinic for the second BEXSERO injection, the lump had decreased in size, but was still present at the site of the previous injection. The patient''s mother requested that the second BEXSERO injection be administered slightly lower on the muscle and the patient did not have an adverse reaction to the second BEXSERO injection.


Changed on 12/24/2020

VAERS ID: 629007 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:Arizona
Vaccinated:2015-12-16
Onset:0000-00-00
Submitted:2016-03-23
Entered:2016-03-23
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MEN: MENINGOCOCCAL (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK AR / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS - / 1 AR / IM

Administered by: Other      Purchased by: Other
Symptoms: Injection site erythema, Injection site mass, Injection site pain, Injection site warmth, Myalgia

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016037781

Write-up: This case was reported by a consumer via call center representative and described the occurrence of injection site lump in a 16-year-old female patient who received BEXSERO. Concomitant products included Meningococcal polysaccharide groups A, C, W-135, Y conjugate vaccine. On 16th December 2015, the patient received the 1st dose of BEXSERO (intramuscular). On an unknown date, an unknown time after receiving BEXSERO, the patient experienced injection site lump and injection site warmth. On an unknown date, the outcome of the injection site lump and injection site warmth were unknown. It was unknown if the reporter considered the injection site lump and injection site warmth to be related to BEXSERO. Additional details were received as follows: The patient received the 1st dose in the series of BEXSERO. She also received a meningococcal vaccine on the same day (she believed it might have been brand name MENVEO, but was unsure). The 2 vaccines were administered in different arms. The patient developed a golf-ball sized lump at the site of the BEXSERO vaccine. The lump was red, warm to the touch, and sore for 1 month. The muscle soreness was severe enough to prevent the patient from driving. The patient attempted applying heat and ice, but the pain did not resolve. The patient also took over-the-counter pain medications to relieve the pain. When the patient presented to the clinic for the second BEXSERO injection, the lump had decreased in size, but was still present at the site of the previous injection. The patient''s mother requested that the second BEXSERO injection be administered slightly lower on the muscle and the patient did not have an adverse reaction to the second BEXSERO injection.


Changed on 12/30/2020

VAERS ID: 629007 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:Arizona
Vaccinated:2015-12-16
Onset:0000-00-00
Submitted:2016-03-23
Entered:2016-03-23
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MEN: MENINGOCOCCAL (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK AR / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS - / 1 AR / IM

Administered by: Other      Purchased by: Other
Symptoms: Injection site erythema, Injection site mass, Injection site pain, Injection site warmth, Myalgia

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016037781

Write-up: This case was reported by a consumer via call center representative and described the occurrence of injection site lump in a 16-year-old female patient who received BEXSERO. Concomitant products included Meningococcal polysaccharide groups A, C, W-135, Y conjugate vaccine. On 16th December 2015, the patient received the 1st dose of BEXSERO (intramuscular). On an unknown date, an unknown time after receiving BEXSERO, the patient experienced injection site lump and injection site warmth. On an unknown date, the outcome of the injection site lump and injection site warmth were unknown. It was unknown if the reporter considered the injection site lump and injection site warmth to be related to BEXSERO. Additional details were received as follows: The patient received the 1st dose in the series of BEXSERO. She also received a meningococcal vaccine on the same day (she believed it might have been brand name MENVEO, but was unsure). The 2 vaccines were administered in different arms. The patient developed a golf-ball sized lump at the site of the BEXSERO vaccine. The lump was red, warm to the touch, and sore for 1 month. The muscle soreness was severe enough to prevent the patient from driving. The patient attempted applying heat and ice, but the pain did not resolve. The patient also took over-the-counter pain medications to relieve the pain. When the patient presented to the clinic for the second BEXSERO injection, the lump had decreased in size, but was still present at the site of the previous injection. The patient''s mother requested that the second BEXSERO injection be administered slightly lower on the muscle and the patient did not have an adverse reaction to the second BEXSERO injection.


Changed on 5/7/2021

VAERS ID: 629007 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:Arizona
Vaccinated:2015-12-16
Onset:0000-00-00
Submitted:2016-03-23
Entered:2016-03-23
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MEN: MENINGOCOCCAL (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK AR / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS - / 1 AR / IM

Administered by: Other      Purchased by: Other
Symptoms: Injection site erythema, Injection site mass, Injection site pain, Injection site warmth, Myalgia

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016037781

Write-up: This case was reported by a consumer via call center representative and described the occurrence of injection site lump in a 16-year-old female patient who received BEXSERO. Concomitant products included Meningococcal polysaccharide groups A, C, W-135, Y conjugate vaccine. On 16th December 2015, the patient received the 1st dose of BEXSERO (intramuscular). On an unknown date, an unknown time after receiving BEXSERO, the patient experienced injection site lump and injection site warmth. On an unknown date, the outcome of the injection site lump and injection site warmth were unknown. It was unknown if the reporter considered the injection site lump and injection site warmth to be related to BEXSERO. Additional details were received as follows: The patient received the 1st dose in the series of BEXSERO. She also received a meningococcal vaccine on the same day (she believed it might have been brand name MENVEO, but was unsure). The 2 vaccines were administered in different arms. The patient developed a golf-ball sized lump at the site of the BEXSERO vaccine. The lump was red, warm to the touch, and sore for 1 month. The muscle soreness was severe enough to prevent the patient from driving. The patient attempted applying heat and ice, but the pain did not resolve. The patient also took over-the-counter pain medications to relieve the pain. When the patient presented to the clinic for the second BEXSERO injection, the lump had decreased in size, but was still present at the site of the previous injection. The patient''s mother requested that the second BEXSERO injection be administered slightly lower on the muscle and the patient did not have an adverse reaction to the second BEXSERO injection.


Changed on 5/21/2021

VAERS ID: 629007 Before After
VAERS Form:1
Age:16.0
Sex:Female
Location:Arizona
Vaccinated:2015-12-16
Onset:0000-00-00
Submitted:2016-03-23
Entered:2016-03-23
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
MEN: MENINGOCOCCAL (NO BRAND NAME) / UNKNOWN MANUFACTURER - / UNK AR / UN
MENB: MENINGOCOCCAL B (BEXSERO) / NOVARTIS VACCINES AND DIAGNOSTICS - / 1 AR / IM

Administered by: Other      Purchased by: Other
Symptoms: Injection site erythema, Injection site mass, Injection site pain, Injection site warmth, Myalgia

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications: No other medications
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data:
CDC 'Split Type': US2016037781

Write-up: This case was reported by a consumer via call center representative and described the occurrence of injection site lump in a 16-year-old female patient who received BEXSERO. Concomitant products included Meningococcal polysaccharide groups A, C, W-135, Y conjugate vaccine. On 16th December 2015, the patient received the 1st dose of BEXSERO (intramuscular). On an unknown date, an unknown time after receiving BEXSERO, the patient experienced injection site lump and injection site warmth. On an unknown date, the outcome of the injection site lump and injection site warmth were unknown. It was unknown if the reporter considered the injection site lump and injection site warmth to be related to BEXSERO. Additional details were received as follows: The patient received the 1st dose in the series of BEXSERO. She also received a meningococcal vaccine on the same day (she believed it might have been brand name MENVEO, but was unsure). The 2 vaccines were administered in different arms. The patient developed a golf-ball sized lump at the site of the BEXSERO vaccine. The lump was red, warm to the touch, and sore for 1 month. The muscle soreness was severe enough to prevent the patient from driving. The patient attempted applying heat and ice, but the pain did not resolve. The patient also took over-the-counter pain medications to relieve the pain. When the patient presented to the clinic for the second BEXSERO injection, the lump had decreased in size, but was still present at the site of the previous injection. The patient''s mother requested that the second BEXSERO injection be administered slightly lower on the muscle and the patient did not have an adverse reaction to the second BEXSERO injection.

New Search

Link To This Search Result:

https://www.medalerts.org/vaersdb/findfield.php?IDNUMBER=629007&WAYBACKHISTORY=ON


Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166